CAM
AMAM

Cormorant Asset Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Cormorant Asset Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,231,000
Closed -$160M – 65
2023
Q4 		$160M Buy
11,231,000
+1,307,311
+13% +$14.9M 7.64% 2
2023
Q3 		$114M Buy
9,923,689
+307,534
+3% +$4.19M 6.66% 3
2023
Q2 		$158M Buy
9,616,155
+1,116,155
+13% +$14M 8.87% 2
2023
Q1 		$75.8M Buy
8,500,000
+6,163,611
+264% +$31M 4.99% 5
2022
Q4 		$5.3M Hold
2,336,389
– – 0.35% 55
2022
Q3 		$2.52M Sell
2,336,389
-149,997
-6% -$309K 0.18% 57
2022
Q2 		$6.59M Hold
2,486,386
– – 0.5% 47
2022
Q1 		$10.2M Hold
2,486,386
– – 0.79% 39
2021
Q4 		$22.5M Hold
2,486,386
– – 1.34% 23
2021
Q3 		$33.1M Hold
2,486,386
– – 1.34% 21
2021
Q2 		$47M Buy
+2,486,386
New +$42.4M 1.6% 18

Cormorant Asset Management's AMAM Position: Q1 2024 in Review

Cormorant Asset Management sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 11,231,000 shares — an estimated $160M sold.

Cormorant Asset Management first reported a position in AMAM in Q2 2021 and held it in 11 quarters. The position peaked at $160M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

  • Cormorant Asset Management reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 11,231,000 Ambrx Biopharma Inc shares in Q1 2024, an estimated $160M.
  • Cormorant Asset Management first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 11 quarters.
  • Cormorant Asset Management's Ambrx Biopharma Inc position peaked at $160M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.